UNSPSC 51191529: Amanozine

This classification denotes a diuretic with the molecular formula C9H9N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X43W7JDA8L, chemically known as 1,3,5-triazine-2,4-diamine, n-phenyl-, monohydrochloride but generally known as amanozine, which bears US NIH Compound Identifier 10832. Amanozine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amanozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05388MIG.

UNSPSC 51191529 Amanozine, a Commodity code, covers chemical products used in state and local water treatment and pharmaceutical distribution operations. Recent solicitations show the code encompasses sodium bisulfite for municipal water pollution control facilities and generic multi-source pharmaceuticals and over-the-counter products for state and local government healthcare operations. The issuing bodies span municipal utilities, state procurement offices, and cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant multi-jurisdictional buyer under this code, extending purchasing authority across participating states including Oregon.

The City of Meriden, Connecticut, posted an IFB (solicitation B027-15) on July 8, 2026, for sodium bisulfite chemical supply with bids due July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000 and performance and payment bonds. MMCAP issued an RFP (S1070000015802) posted January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with awarded contracts effective July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent of evaluation and requires vendors to maintain commercial general liability of $5,000,000 per occurrence and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Activity under this code concentrates in Connecticut and Minnesota-anchored cooperative purchasing structures, with vendor qualification requirements including insurance thresholds, regulatory compliance certifications, and established relationships with authorized distribution networks.